Blood loss and subsequent transfusions are associated with major morbidity and mortality.
The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic …

Experience with tranexamic acid, an indirect fibrinolytic inhibitor, started as soon as it was
released from Shosuke Okamoto's lab in the early 1960s. It was first prescribed to females …

Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a
wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug …

Hemorrhage is the leading cause of preventable death in combat trauma and the secondary
cause of death in civilian trauma. A significant number of deaths due to hemorrhage occur …

Background In response to the World Health Organization call for research on alternative
routes for tranexamic acid (TXA) administration in women with postpartum haemorrhage, we …

Fibrinolysis is a physiologic component of hemostasis that functions to limit clot formation.
However, after trauma or surgery, excessive fibrinolysis may contribute to coagulopathy …

Background To examine the safety and efficacy of topical use of tranexamic acid (TA) in total
knee arthroplasty (TKA). Methods An electronic literature search of PubMed Medline; Ovid …

Background The efficacy of tranexamic acid (TXA) to reduce perioperative blood loss and
allogeneic blood transfusion in cardiac surgeries has been proved in previous studies, but …

Background It is unclear whether high-dose regimens of tranexamic acid in cardiac surgery
(total dose, 80 to 100 mg/kg) confer a clinical advantage over low-dose regimens (total dose …

Abstract Purpose In this Continuing Professional Development module, we review the
practical pharmacology of tranexamic acid and its clinical use in trauma, obstetrics, and …